Idea Transcript
View ScienceDirect over a secure connection: switch to HTTPS
Journals
Books
Register
Sign in
Outline
Purchase PDFPurchase
Search ScienceDirect
Export
Advanced
Outline Highlights Abstract Keywords Introduction Materials and Methods Results Discussion Conflict of interest References
Show full outline
Figures (5)
Tables (1) Table 1
Gynecologic Oncology Volume 130, Issue 1, July 2013, Pages 107-114
An international assessment of ovarian cancer incidence and mortality Kimberly A. Lowe a
1
, Victoria M. Chia b, Aliki Taylor b, Cynthia O’Malley e, Michael Kelsh b, Muhima Mohamed a, Fionna S. Mowat c , Barbara Goff d
Show more https://doi.org/10.1016/j.ygyno.2013.03.026
Get rights and content
Highlights •
We assessed the global epidemiology of ovarian cancer and examined changes in worldwide incidence and mortality.
•
There was a modest decrease in incidence and significant increases in 12-, 24-, and 60-month survival in the US.
•
There is wide variation in the worldwide incidence of ovarian cancer, with the lowest rates consistently in China.
Abstract Objective To assess and characterize the temporal variation in ovarian cancer incidence and mortality by age within countries in the Americas, Europe, Asia, and Oceania. Methods/Materials Data from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program in the United States (U.S.) were used to assess ovarian cancer incidence rates (1998–2008) and mortality rates, (1988–2007 for 12-month survival, 1988–2006 for 24-month survival, and 1988–2003 for 60-month survival), stratified by age at diagnosis. Data from GLOBOCAN were used to calculate country-specific incidence rates for 2010 and 2020 and case-fatality rates for 2010. Results A statistically significant decrease in Annual Percent Change (APC) of ovarian cancer incidence was observed in the U.S. for all women (− 1.03%), among women who were diagnosed at < 65 years of age (− 1.09%) and among women who were diagnosed at ≥ 65 years of age (− 0.95%). There was a statistically significant increase in the observed APC for survival at 12-months (0.19%), 24-months (0.58%), and 60-months (0.72%) for all women; however, 5-year survival for advanced stage (III or IV) disease was low at less than 50% for women < 65 years and less than 30% for women ≥ 65 years. Global results showed a wide range in ovarian cancer incidence rates, with China exhibiting the lowest rates and the Russian Federation and the United Kingdom exhibiting the highest rates. Conclusions Ovarian cancer survival has shown modest improvement from a statistical perspective in the U.S. However, it is difficult to ascertain how clinically relevant these improvements are at the population or patient level.
Previous article
Keywords Ovarian cancer; Incidence; Survival; GLOBOCAN; SEER
Choose an option to locate/access this article: Check if you have access through your login credentials or your institution.
Check Access or
Purchase Rent at DeepDyve or
Next article
Check for this article elsewhere
Recommended articles
1
Citing articles (79)
Now at Amgen Inc, Seattle, WA, USA.
Copyright © 2013 Elsevier Inc. All rights reserved.
Recommended articles Global ovarian cancer health disparities Gynecologic Oncology, Volume 129, Issue 1, 2013, pp. 258-264 Download PDF
View details
Ovarian cancer in France: Trends in incidence, mortality and survival, 1980–2012 Gynecologic Oncology, Volume 139, Issue 2, 2015, pp. 324-329 Download PDF
View details
Why have ovarian cancer mortality rates declined? Part I. Incidence Gynecologic Oncology, Volume 138, Issue 3, 2015, pp. 741-749 Download PDF
View details
View more articles
Citing articles (79) Article Metrics Captures Exports-Saves:
6
Readers:
73
Citations Citation Indexes:
79
View details
About ScienceDirect
Remote access
Shopping cart
Contact and support
Terms and conditions
Privacy policy
Cookies are used by this site. For more information, visit the cookies page. Copyright © 2017 Elsevier B.V. or its licensors or contributors. ScienceDirect ® is a registered trademark of Elsevier B.V.